Renatus Tactical Acquisition Corp I director Fattal resigns, Nasdaq audit committee notice
Matan Fattal resigned as a director and from the Audit, Compensation, and Nominating and Corporate Governance committees, effective June 5, 2026, and the filing says the resignation was not due to any disagreement with the company or its board. Following his departure, the company notified Nasdaq that it no longer meets audit committee and board independence requirements, and it intends to rely on cure periods while it searches for an independent director.
Key points
- Matan Fattal resigned as director and from three board committees, effective June 5, 2026.
- On June 8, 2026, the company notified Nasdaq that its audit committee no longer meets the three-member, independent-director requirement under Rule 5605(c)(2)(A).
- The board now has two independent directors, two non-independent directors, and one vacant seat, so it no longer has an independent majority, a temporary noncompliance under Rule 5605(b).
- The company intends to use Nasdaq cure periods and is searching for an independent director to join the board and audit committee.
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.